Product transition updates

Lifeblood transition to split apheresis cryoprecipitate – now complete for all states  

Lifeblood’s inventory of large-dose apheresis cryoprecipitate has been exhausted in all states.   

With the transition complete, we're now supplying only whole blood and split apheresis cryoprecipitate to laboratories.  

Whole blood or split apheresis cryoprecipitate units are equivalent and interchangeable. The recommended adult dose is 10 units of either presentation.  

Transfusion Service Providers may continue to have a mixed inventory of large dose and split apheresis units until remaining stocks of large-dose units are used.  

Large-dose apheresis cryoprecipitate units were not manufactured after December 2024 - these units have a shelf life of 12 months when stored at -25 °C or below. The timeframe for transition of local laboratories will vary and depends on cryoprecipitate inventory levels, including by blood group, and on any returns from satellite/regional sites for use before expiry.  

Refer to your local health service communications or transfusion laboratory for updates on the transition.    

More information: Cryoprecipitate | Lifeblood
 

Introduction of Beriplex® AU to replace Beriplex® P/N 

The transition of Australia's prothrombin complex concentrate (PCC) product, Beriplex®, is about to start with staggered start dates nationally from the end of March to early May 2025.  

Lifeblood will be running down our inventory of Beriplex® P/N before switching to Beriplex® AU and have communicated with customers/laboratories the details of the transition, including to continue to place orders for Beriplex® P/N until we send notification of the transition in their region.  

Below is the estimated timing for the transition:  

• QLD and SA – week commencing 31 March 2025  
• VIC, TAS and WA – week commencing 14 April 2025  
• ACT and NSW – week commencing 28 April 2025  
• NT – week commencing 5 May 2025  

The following resources are available to update your laboratory and hospital policies and documents: 

• Transition of Australia's domestic plasma products | National Blood Authority  
• The Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) updated Warfarin Reversal Guidelines  
• Product Information and Consumer Medical Information for Beriplex® AU available on Therapeutic Goods Administration (TGA) 
• CSL Behring website